Educational Grants

Alkermes Education Grants

Click Here to Apply

Alkermes contributes to independent education by supporting educational grants. Our focus areas include educational activities with pragmatic approaches to improve patient care and public health in the domains of schizophrenia, depression, and alcohol and opioid dependence. We expect to contribute to a better and expanded understanding of the underlying mechanisms of disease and their relevance to medications that address those characteristics, as well as the overall treatment in a broad sense that includes psychosocial methods. Alkermes’ educational grant funds may not be used to support overhead expenses of the applicant or for any other institution affiliated with the applicant. Grant requests must be unsolicited, should typically have multiple funders, support education on a wide range of treatment options, not promote a particular medicine and must not provide nor promise to Alkermes any tangible benefit.

Areas of Interest

Substance Use Disorders

Alkermes is currently accepting educational proposals that aim to reduce clinical barriers to the initiation of Medication-Assisted Treatment (MAT) for Opioid Use Disorder and improve adherence resulting in improved clinical outcomes for patients through educational programs. Target audiences of highest priority are medical students, addiction care teams including treatment counselors, nurses, and pharmacists, and addiction specialists/physicians.

Special attention will be given to programs that will reach areas of highest educational need (e.g. medical schools, the VA system, criminal justice settings, hospitals, and outpatient clinics). Collaborations between medical societies, patient groups, academic institutions, and/or medical education companies are encouraged.

Educational activities must be accredited (CME/CE), and the maximum award size will be up to $150,000. Programs with additional funding sources are preferred.

Proposals must be submitted by September 15, 2018 through the Alkermes Grant Management System. Recipients will be selected by the Alkermes Grants Review Committee, and recipients will be notified in October 2018.

Alkermes is still accepting proposals that address the funding areas of interest listed below.

  • Increasing awareness and understanding of opioid use disorder, alcohol use disorder, and the medication-assisted treatment options
  • Reducing barriers to the initiation of treatment and retention in treatment
  • Implementing medication-assisted treatment within healthcare systems
  • Treatment of special populations including:
    • Criminal justice
    • Young adults
  • Increasing awareness of addiction treatment guidelines and policies


  • Understanding the role adverse effects and adherence play in the effectiveness of treatment for schizophrenia, including treatment resistant schizophrenia, in order to improve clinical outcomes
  • The role of Long-Acting Injectables (LAIs) across the lifespan of schizophrenia
  • Enhancement of patient care in schizophrenia
  • Short and long-term complications associated with antipsychotics
  • Psychopharmacology of LAIs (PK/PD)
  • The role of LAIs in managing gaps in transitions of care
  • Challenges patients with schizophrenia encounter in the treatment and progression of their disease to decrease suboptimal outcomes
  • Managing co-occurring illnesses (e.g., schizophrenia and substance use disorder)
  • Evaluate clinical decision models for treatment and continued management of schizophrenia

Major Depression Disorder (MDD)

  • Education on new understanding of the pathophysiology of MDD
  • Exploring existing and novel (e.g., non-monoamine) pharmacological mechanisms for MDD
  • Recognition and management of patients with MDD with an inadequate response to current antidepressant therapy

Education grants will not be awarded to or for:

  • Individuals or a healthcare professional’s private practice
  • Any charity or foundation associated with or controlled by an individual healthcare professional or healthcare professional’s private practice
  • Organizations that discriminate on the basis of race, color, sex, sexual orientation, religion, age, national origin or disability
  • Fundraising event of a potential customer (e.g., treatment center or hospital) where the proceeds are being used to cover general operational and routine business costs
  • Events that have already occurred
  • Political organizations, campaigns and activities
  • Religious organizations or groups whose activities are primarily sectarian in purpose
  • Programs or proposals that supplement an organization’s income or offset its expenses in a manner that benefits, directly or indirectly, a physician’s compensation

Alkermes is committed to complying with all applicable regulations and codes pertaining to education grants. Alkermes follows the requirements of the Compliance Program Guidance for Pharmaceutical Manufacturers issued by the Department of Health and Human Services Office of the Inspector General (“OIG Guidelines”), the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals (“PhRMA Code”), the FDA Guidance to Industry Supported Scientific and Educational Activities, and the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support. Alkermes does not provide support for education programs that are intended to encourage, induce, or influence any grant recipient to purchase, prescribe, refer, recommend, sell, administer, or arrange for the purchase, sale or recommendation, or formulary placement of any Alkermes’ product.

To submit an education grant request, please register and submit your completed application and supporting documentation through Alkermes’ education grant management system located here.